Skip to main content

Advertisement

SpringerLink
Log in

Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Detection of BCR-ABL1 mutations that confer resistance to tyrosine kinase inhibitors is important for management of patients with t(9;22);BCR-ABL1-positive (Ph+) leukemias. Testing is often performed using Sanger sequencing (SS) which has relatively poor sensitivity. Given the widespread adoption of next generation sequencing (NGS), we sought to reevaluate the testing in the context of NGS methods. We developed an NGS-based BCR-ABL1 mutation test on the Ion Torrent Personal Genome Machine (PGM) to test for resistance mutations, primarily in the kinase domain in BCR-ABL1. We analyzed 508 clinical samples from patients with Ph+ leukemias. In a subset of these samples (n = 97), we conducted a comparison of the NGS results to a classical SS-based test. NGS facilitated detection of low-level mutations (<20 % allele frequency) that were not detectable by SS. In a subset of cases with multiple mutations, NGS was also able to determine if two mutations were on the same molecule (compound) or on separate molecules (polyclonal) but this was limited by the distance between mutated positions and by the effects of apparent distance-dependent PCR recombination. We found 22 compound mutations that centered on one or two key residues including two novel compound mutants: Q252H/Y253H and F311Y/F359I. The advantages of NGS make it a superior method for inventorying BCR-ABL1 resistance mutations. However, data analysis may be complicated by short read lengths and the effects of PCR recombination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J (2009) Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037–2043. doi:10.1182/blood-2009-01-197715

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116(17):3278–3285. doi:10.1182/blood-2008-10-183665

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Baccarani M, Pane F, Saglio G (2008) Monitoring treatment of chronic myeloid leukemia. Haematologica 93(2):161–169. doi:10.3324/haematol.12588

    Article  PubMed  CAS  Google Scholar 

  4. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW (2013) BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 121(3):489–498. doi:10.1182/blood-2012-05-431379

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 122(9):1634–1648. doi:10.1182/blood-2013-03-487728

    Article  PubMed  CAS  Google Scholar 

  6. Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintas-Cardama A (2014) Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A 111(9):3550–3555. doi:10.1073/pnas.1321173111

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075–2088. doi:10.1056/NEJMoa1205127

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401–412. doi:10.1016/j.ccr.2009.09.028

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26(3):428–442. doi:10.1016/j.ccr.2014.07.006

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Schumacher JA, Szankasi P, Bahler DW, Ho AK, Kelley TW (2011) A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation. J Clin Pathol 64(7):618–625. doi:10.1136/jcp.2011.089193

    Article  PubMed  CAS  Google Scholar 

  11. Parker WT, Ho M, Scott HS, Hughes TP, Branford S (2012) Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood 119(10):2234–2238. doi:10.1182/blood-2011-08-375535

    Article  PubMed  CAS  Google Scholar 

  12. Judo MS, Wedel AB, Wilson C (1998) Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res 26(7):1819–1825

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S (2014) Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood 124(1):153–155. doi:10.1182/blood-2014-05-573485

    Article  PubMed  CAS  Google Scholar 

  14. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Muller MC, Ernst T, Rosti G, Porkka K, Baccarani M, Cross NC, Martinelli G (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215. doi:10.1182/blood-2010-12-326405

    Article  PubMed  CAS  Google Scholar 

  15. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118(17):4567–4576. doi:10.1182/blood-2011-05-355594

    Article  PubMed  CAS  Google Scholar 

  16. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119(15):3403–3412. doi:10.1182/blood-2011-11-390120

    Article  PubMed  CAS  Google Scholar 

  17. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, Investigators P (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369(19):1783–1796. doi:10.1056/NEJMoa1306494

    Article  PubMed  CAS  Google Scholar 

  18. Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S (2013) BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer 109(6):1593–1598. doi:10.1038/bjc.2013.318

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9):2562–2569. doi:10.1172/JCI30890

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123–3127. doi:10.1002/cncr.26679

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ARUP Laboratories, Salt Lake City, UT, USA

    Philippe Szankasi & Jonathan A. Schumacher

  2. Department of Pathology, University of Utah, Salt Lake City, UT, 84112, USA

    Todd W. Kelley

Authors
  1. Philippe Szankasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan A. Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Todd W. Kelley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd W. Kelley.

Ethics declarations

Conflict of interest

P.S. and J.A.S. are employed by ARUP Laboratories. T.W.K. is employed by the University of Utah, Department of Pathology.

Funding

This study was funded by ARUP Laboratories (grant number not applicable), a reference laboratory owned and operated by the University of Utah, Department of Pathology.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Szankasi, P., Schumacher, J.A. & Kelley, T.W. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing. Ann Hematol 95, 201–210 (2016). https://doi.org/10.1007/s00277-015-2539-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2539-0

Keywords

Search

Navigation